# Zimmer Biomet **Source:** https://geo.sig.ai/brands/zimmer-biomet **Vertical:** Healthcare Tech **Subcategory:** Orthopedic Implants **Tier:** Leader **Website:** zimmer-biomet.com **Last Updated:** 2026-04-14 ## Summary Zimmer Biomet (ZBH) reported ~$7.7B revenue in FY2024. Leading maker of orthopedic implants for knee and hip replacement surgeries, with robotics and digital surgery platforms. HQ: Warsaw, IN. ## Company Overview Zimmer Biomet Holdings, Inc. is one of the world's largest musculoskeletal healthcare companies, designing, manufacturing, and distributing orthopedic implants, spinal devices, dental implants, and surgical instrumentation. The company's core products are total knee and total hip replacement systems — the implants that allow surgeons to replace arthritic or damaged joints, enabling millions of patients to regain mobility and reduce chronic pain. Formed through Zimmer Holdings' $13.4 billion acquisition of Biomet in 2015, the company serves over 25 million patients annually. Zimmer Biomet reported approximately $7.7 billion in revenue in FY2024, with the Knee segment (Persona, NexGen systems) and Hip segment (Taperloc, Vivacit-E) representing the majority. The company's ROSA Robotics platform is central to its strategy — the ROSA Knee and ROSA Hip surgical systems guide surgeons through robotic-assisted joint replacement, improving implant positioning accuracy and patient outcomes. Adoption of robotic surgery is a significant growth driver: surgeons trained on specific robotic platforms tend to use the corresponding implants, creating a powerful competitive dynamic. Zimmer Biomet also offers ZBEdge digital health analytics for population health management. The orthopedic implant market benefits from powerful demographic tailwinds: the aging baby boomer population is reaching peak joint replacement age, and increasing rates of obesity and activity in middle age are accelerating joint wear in younger patients. Zimmer Biomet is navigating a competitive robotics market where Stryker (Mako), Smith+Nephew, and Medtronic all offer competing platforms — differentiation through outcomes data, surgeon training programs, and integrated digital ecosystems will determine long-term share. ## Frequently Asked Questions ### What does Zimmer Biomet make? Zimmer Biomet makes orthopedic implants for total knee replacement, total hip replacement, and spinal surgery, plus the ROSA robotic surgery platform that assists surgeons in precise implant placement. ### What is the ROSA Robotic System? ROSA (Robotic Surgical Assistant) is Zimmer Biomet's surgical robot that guides surgeons through knee and hip replacement procedures with enhanced imaging and real-time feedback, improving implant positioning accuracy. Robotic adoption is one of the key growth drivers in orthopedics. ### What is Zimmer Biomet's ticker? Zimmer Biomet Holdings trades on the NYSE under the ticker ZBH. ### Why is the orthopedic market growing? Joint replacements are growing driven by aging baby boomers reaching peak joint-replacement age (60s–70s), rising obesity rates accelerating joint wear, and improved implant longevity enabling younger patients to receive replacements. Over 1 million knee and hip replacements are performed annually in the U.S. ### How does the ROSA robotic system improve surgical outcomes? ROSA provides surgeons with real-time guidance based on 3D imaging and patient anatomy, enabling more precise implant positioning than conventional surgical techniques. For knee replacement, studies show ROSA-assisted procedures achieve implant alignment within tighter tolerances than manual technique — potentially improving long-term implant longevity and reducing the mechanical causes of early revision surgery. Surgical robots like ROSA also reduce outlier cases where positioning significantly deviates from plan. ### What is Zimmer Biomet's strategy for the dental and spine markets? Zimmer Biomet spun off its spine and dental businesses into ZimVie (NYSE: ZIMV) in 2022, allowing both companies to focus on their core markets. Zimmer Biomet now focuses exclusively on orthopedic reconstruction (knee, hip, shoulder) and robotic surgery. This focused strategy allows deeper investment in ROSA's next-generation capabilities and the implant innovation required to maintain share against Stryker (Mako robot), DePuy Synthes (Johnson & Johnson), and Smith+Nephew in the competitive robotic orthopedics market. ### How does Zimmer Biomet compete with Stryker's Mako robotic system? Stryker's Mako is the market leader in robotic orthopedic surgery by installed base. Zimmer Biomet's ROSA competes by offering comparable robotic guidance with Zimmer Biomet's implant compatibility — surgeons who prefer ZB implants (particularly for knee procedures) benefit from ROSA's optimization for ZB implant geometry. Both platforms are growing because robotic orthopedic surgery overall is expanding faster than the total joint replacement market, with robotic procedures taking share from conventional manual technique. ### What is the outlook for orthopedic implant market growth? The US orthopedic reconstruction market grows approximately 4-6% annually, driven by aging demographics, obesity-related joint wear, and improved implant outcomes that support performing procedures in younger patients. Medicare covers joint replacement for qualifying patients, and private insurance coverage is standard — making it a high-volume, well-reimbursed procedure with strong demographic tailwinds through 2040 as baby boomers reach peak replacement age. International markets (Europe, Asia-Pacific) offer additional growth opportunities. ## Tags b2b, healthtech, manufacturing, saas, public --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*